IINN

Company Overview — What Does Inspira Technologies OXY B.H.N. Ltd Do?

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel. Inspira Technologies OXY B.H.N. Ltd (IINN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Dagi S. Ben-Noon and employs approximately 20 people. With a market capitalization of $20M, IINN is one of the notable companies in the Healthcare sector.

Inspira Technologies OXY B.H.N. Ltd (IINN) Stock Rating — Avoid (April 2026)

As of April 2026, Inspira Technologies OXY B.H.N. Ltd receives a Avoid rating with a composite score of 28.9/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.IINN ranks #3,925 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Inspira Technologies OXY B.H.N. Ltd ranks #672 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IINN Stock Price and 52-Week Range

Inspira Technologies OXY B.H.N. Ltd (IINN) currently trades at $0.42. The stock gained $0.01 (2.2%) in the most recent trading session. The 52-week high for IINN is $1.65, which means the stock is currently trading -74.8% from its annual peak. The 52-week low is $0.40, putting the stock 3.3% above its annual trough. Recent trading volume was 274K shares, suggesting relatively thin trading activity.

Is IINN Overvalued or Undervalued? — Valuation Analysis

Inspira Technologies OXY B.H.N. Ltd (IINN) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.24x, versus the sector average of 2.75x.

At current multiples, Inspira Technologies OXY B.H.N. Ltd trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Inspira Technologies OXY B.H.N. Ltd Profitability — ROE, Margins, and Quality Score

Inspira Technologies OXY B.H.N. Ltd (IINN) earns a quality factor score of 30/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -1022.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -547.9% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IINN Debt, Balance Sheet, and Financial Health

Inspira Technologies OXY B.H.N. Ltd has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $5M.

IINN has a beta of 0.97, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Inspira Technologies OXY B.H.N. Ltd is 26/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Inspira Technologies OXY B.H.N. Ltd Revenue and Earnings History — Quarterly Trend

In TTM 2026, Inspira Technologies OXY B.H.N. Ltd reported revenue of $0 and earnings per share (EPS) of $-0.60. Net income for the quarter was $-11M. Operating income came in at $-11M.

In FY 2024, Inspira Technologies OXY B.H.N. Ltd reported revenue of $0 and earnings per share (EPS) of $-0.60. Net income for the quarter was $-11M. Operating income came in at $-11M.

In FY 2023, Inspira Technologies OXY B.H.N. Ltd reported revenue of $0 and earnings per share (EPS) of $-0.93. Net income for the quarter was $-11M. Operating income came in at $-12M.

In FY 2022, Inspira Technologies OXY B.H.N. Ltd reported revenue of $0 and earnings per share (EPS) of $-1.39. Net income for the quarter was $-15M. Operating income came in at $-15M.

Over the past 6 quarters, Inspira Technologies OXY B.H.N. Ltd has experienced revenue contraction from $0 to $0. Investors analyzing IINN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IINN Dividend Yield and Income Analysis

Inspira Technologies OXY B.H.N. Ltd (IINN) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IINN Momentum and Technical Analysis Profile

Inspira Technologies OXY B.H.N. Ltd (IINN) has a momentum factor score of 18/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 54/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.

IINN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Inspira Technologies OXY B.H.N. Ltd (IINN) ranks #672 out of 838 stocks based on the Blank Capital composite score. This places IINN in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IINN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IINN vs S&P 500 (SPY) comparison to assess how Inspira Technologies OXY B.H.N. Ltd stacks up against the broader market across all factor dimensions.

IINN Next Earnings Date

No upcoming earnings date has been announced for Inspira Technologies OXY B.H.N. Ltd (IINN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IINN? — Investment Thesis Summary

The quantitative profile for Inspira Technologies OXY B.H.N. Ltd suggests caution. The quality score of 30/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Momentum is weak at 18/100, a headwind for near-term performance. High volatility (stability score 26/100) increases portfolio risk.

In summary, Inspira Technologies OXY B.H.N. Ltd (IINN) earns a Avoid rating with a composite score of 28.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IINN stock.

Related Resources for IINN Investors

Explore more research and tools: IINN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IINN head-to-head with peers: IINN vs AZN, IINN vs SLGL, IINN vs VMD.